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ABSTRACT
Q5 HIV-related primary vitreoretinal lymphoma (PVRL) is a subset of primary central nervous system
lymphoma (PCNSL), which is an AIDS-defining disease. Patients are younger than immunocompetent
10 patients who present with PVRL, and generally have very low CD4-counts. Vitritis with multifocal cream-
colored subretinal or sub-retinal pigment epithelial infiltrates, and absence of cystoid macular edema is
typical. Vitreous cytology remains the gold standard for diagnosis, but supplementary tests such as flow
cytometry and genetic analysesQ6 of tumor cells in vitreous samples, and measurement of interleukin-10
level in aqueous or vitreous, may improve diagnostic yields. Diagnosis may also be established by
15 identifying concurrent brain involvement. Treatment includes antiretroviral therapy (ART), systemic
chemotherapy (usually methotrexate-based) and local ocular treatment (including intravitreal metho-
trexate, intravitreal rituximab and ocular external beam radiotherapy). The value of systemic chemother-
apy in the absence of associated PCNSL is uncertain. Prognosis is poor but has improved significantly
compared to the pre-ART era.
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20 Primary vitreoretinal lymphoma (PVRL) is a subset of pri-
mary central nervous system lymphoma (PCNSL) that is first
detected within the eye, and most often is localized to the
vitreous and/or retina.1 It is an aggressive lymphoma that is
associated with a poor prognosis, as many patients ultimately
25 develop intracranial involvement.2 PVRL needs to be differ-
entiated from uveal lymphoma, which affects the choroid,
ciliary body or iris, and may occur as a primary malignancy,
as well as from a secondary manifestation of systemic
lymphoma.3 In this review we focus on PVRL, and specifically
30 PVRL that occurs in the setting of human immunodeficiency
virus (HIV) infection.
PVRL in HIV-positive patients has many similarities to
PVRL in immunocompetent individuals. However, several
important differences exist in epidemiology, pathogenesis,
35 differential diagnosis and management, which necessitates
an adjusted approach in these patients.
Epidemiology
HIV-related PVRL is rare, and the scarce literature on the
subject consists of small case series and case reports.4–12 Even
40 in immunocompetent patients, the incidence of PVRL is low,
estimated at approximately 0.021 to 0.048 in 100 000
people.1,13
PCNSL is one of the acquired immune deficiency syn-
drome (AIDS) defining diseases.14 In the United States,
45 where epidemiology has been well documented, the incidence
of HIV-associated PCNSL increased during the AIDS pan-
demic in the 1990 s, and then declined with the introduction
of antiretroviral therapy (ART).15 However, the risk of PCNSL
remains elevated amongst HIV-infected persons, who have
50a 17-times greater risk of developing the disease compared
to the general population.16 How this increased risk of PCNSL
translates to the risk of PVRL has not been studied.
In immunocompetent patients, the median age of presenta-
tion with PVRL is between 65 and 70 years, with a reported
55range of 15–85 years.2,13 In contrast, HIV-related PVRL pre-
sents at a younger age. The median age in published studies is
38 years, with a range of 26–71 years.4–12 Similar to those with
HIV-related PCNSL, patients with HIV-related PVRL are
severely immunocompromised at presentation with a median
60CD4 count of 14 x 106/L (range 0–44 x 106/L).4–8,17,18
Pathogenesis
Histopathologically, PVRL is usually a high-grade, non-
Hodgkin’s lymphoma of diffuse large B-cell lymphoma subtype,
although T-cell rich B-cell lymphomas and T-cell lymphomas
65have also been described.2,13,19 The pathogenesis of HIV-related
PVRL is poorly understood, but insights may be gained from
studies conducted on specimens obtained from patients with
PCNSL.
HIV-associated PCNSL is strongly linked to Epstein-Barr
70virus (EBV) infection. EBV can be detected in virtually all
histopathologic specimens and in 80% of cerebrospinal fluid
(CSF) specimens of HIV-positive patients with PCNSL.20,21 In
laboratory studies, EBV-infected B-lymphocytes produce
latent membrane protein-1 (LMP-1) which upregulates anti-
75apoptosis proteins (bcl-2, bcl-x) and cell cycle regulation
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proteins (cyclin D2), and inactivates the tumor suppressor
gene, p53, causing the cells to proliferate continuously.22 In
immunocompetent persons, this proliferation is held in check
by T cell immunity, but in HIV-patients, there is loss of EBV-
80 specific CD4 + T cell function, leading to proliferation that is
not regulated and ultimately results in monoclonal malignant
transformation.23
The role of EBV in HIV-associated PVRL is less well-
defined due to the rarity of the disease and paucity of biopsy
85 specimens. Mittra et al. published a case report of PVRL in an
HIV-positive patient, whose retinal biopsy specimen con-
tained EBV, as detected by in situ hybridization.5 In a case
series by Chan et al., EBV was identified on the enucleation
specimens of one of the two patients with HIV-related
90 PVRL.24
HIV infection may directly promote lymphomagenesis.
Vascular endothelial cells are permissive to infection with
the virus, and monolayers of endothelial cells expressing
HIV Tat and Vpu transgenes support adhesion and growth
95 of malignant B cells isolated from cerebrospinal fluid (CSF) of
patients with PCNSL.25,26
In almost all cases, PVRL and PCNSL occur exclusively
within the central nervous system, including the eye compart-
ment. Immunohistochemical studies of tissue samples from
100 HIV-infected and non-infected persons, have demonstrated
the presence of B cell chemokines, including CXCL12 and
CXCL13, in local cell populations, as well as lymphomatous
B cells, suggesting these proteins contribute to localization of
the tumor.27–30
105Clinical Presentation
At first presentation, PVRL typically masquerades as
a chronic intermediate or posterior uveitis. It may show an
initial response to corticosteroid therapy, but subsequently
becomes resistant to this treatment.31
110The most common ocular symptoms are floaters and
blurred vision; eye redness and pain are rare.2 Although the
visual acuity may be reduced, it is often much better than
would be expected from that level of intraocular leukocyte
infiltration. The initial presentation is bilateral in 80% of
115cases.13,32,33
On slit-lamp examination, the hallmark of PVRL is vitritis
and/or multifocal cream-colored subretinal or sub-retinal pig-
ment epithelial deposits of lymphoma cells (Figure 1a).34,35
When these deposits are present, the index of suspicion for
120PVRL should be very high. The vitreous cells tend to not
clump, but rather form strings or sheets of cells along the
vitreous fibrils in an aurora borealis-type pattern that may
obscure details of the posterior pole.36,37 The subretinal infil-
trates vary in size from small punctate lesions to larger pla-
125que-like confluent areas, and may be associated with retinal
pigment epithelial changes. Other presentations include ret-
inal infiltration, retinal vasculitis that may be occlusive, and
optic disc swelling.32,33,38
Cystoid macular edema is usually absent.32 This is an
130important diagnostic clue, since patients with inflammatory
or infectious uveitis entities with marked vitritis typically have
macular edema. The posterior segment findings may be




Figure 1. Presentation of a patient with PVRL and concurrent PCNSL. (a). Fundus photograph demonstrating vitreous haze and inferotemporal multiple cream-
colored punctate subretinal infiltrates. (b). Spectral domain OCT showing hyperreflective material in the subretinal and sub-RPE space. (c). Fundus autofluorescence
demonstrating hyperfluorescent spots corresponding to lymphoma infiltrates, and hypofluorescent spots corresponding to RPE atrophy. (d). Contrasted T1-weighted
MRI showing a space-occupying lesion in the left parieto-occipital lobe with vasogenic edema and mild midline shift.






aqueous cells and flare, and keratic precipitates, but posterior
135 synechiae are typically absent.32,38
Approximately 40% of immunocompetent patients with
PVRL have concurrent PCNSL at presentation.13 Similarly, con-
current PCNSL inHIV-related PVRL has also been reported, but
the frequency of the association is unknown.4,6,7,12 The most
140 common neurological symptoms are cognitive deterioration and
behavioral changes, but patients may also present with head-
aches, hemiparesis, aphasia, seizure and/or ataxia.32,39
Differential Diagnosis
PVRL has a wide differential diagnosis, but for patients with
145 HIV-related PVRL, who are severely immunocompromised,
infectious causes are the most important.40
When diffuse subretinal infiltration of lymphoma cells
occurs, the clinical signs may be easily confused with a viral
retinitis. In fact, most of the published cases of HIV-related
150 PVRL were initially misdiagnosed and treated as cytomegalo-
virus (CMV) retinitis.6,7,10,12 For those patients in whom the
subretinal infiltrates are punctate and multifocal, PVRL may
present as a multifocal chorioretinitis, and when perivascular
infiltration of lymphoma cells occurs, the tumor may mas-
155 querade as a retinal vasculitis. These presentations may then
be incorrectly attributed to infections, such as ocular syphilis,
tuberculosis or toxoplasmosis, or fungal endophthalmitis.5,10
Infectious uveitis and PVRL may also occur concomitantly
or sequentially in HIV-positive individuals. Stanton et al.
160 reported a patient with simultaneous CMV retinitis and
PVRL that were diagnosed on vitreous biopsy cytology, and
confirmed at autopsy.12 Rivero et al. described a patient with
CMV retinitis that was successfully treated with intravenous
ganciclovir, who developed PVRL one year later.7 At
165 the second presentation, the eyes had more dense vitritis
and areas of retinal perivasculitis, which would be atypical
of CMV retinitis but could easily be misdiagnosed as an
immune reconstitution uveitis.
Diagnosis
170 PVRL is notoriously difficult to diagnose, particularly in
patients with concomitant HIV infection. The average dura-
tion of symptoms preceding definitive diagnosis varies
between 13 and 24 months in literature published in the
1990 s.41,42 More recent studies indicate that diagnosis is
175 now achieved in 80% of patients within 6 to 12 months due
to an increased awareness of the disease and improved diag-
nostic techniques.2,33,34,39
Ocular Imaging
Ocular imaging may aid considerably when making the diag-
180 nosis of PVRL. Optical coherence tomography (OCT) most
commonly demonstrates the lymphomatous infiltrates as
hyperreflective material in the subretinal space, either as dis-
crete nodules or confluent plaques (Figure 1b). Similarly,
hyperreflective material may also be seen in the sub-RPE
185 space, either as RPE undulations or confluent plaques between
the retinal pigment epithelium and Bruch’s membrane.43
OCT demonstrates choroidal sparing in PVRL, which is
a particularly useful diagnostic feature. Vertical hyperreflec-
tive columns that extend between the retinal nerve fiber layer
190and retinal pigment epithelium have also been described,
hypothesized to represent early micro-infiltration extending
from the retinal vessels into the subretinal and subretinal
pigment epithelial spaces, where the lymphoma cells subse-
quently proliferate.44
195Fundus fluorescein angiography may demonstrate hypo-
fluorescence in areas of lymphomatous infiltration, creating
a “leopard-spot” appearance, and window defects in areas of
retinal pigment epithelial atrophy.45,46 On fundus autofluor-
escence the inverse is observed, with hyperfluorescent spots
200corresponding to the tumor infiltrates, and hypofluorescent
areas corresponding to the epithelial atrophy (Figure 1c).47
Diagnostic Vitrectomy
The gold standard for PVRL diagnosis in HIV-positive
patients, like HIV-negative patients, is the identification of
205PVRL cells on ocular samples, which may include vitreous or
chorioretinal biopsy, or rarely, an enucleated globe.
Corticosteroid treatment should be held for approximately
one month prior to vitrectomy to minimize the lympholytic
effect that may reduce cell yield.48,49
210Typically, a 23- or 25-gauge 3-port diagnostic vitrectomy is
performed, and 1–2 ml of undiluted vitreous is obtained
before the infusion is opened. Lymphoma cells are extremely
fragile and degenerate quickly. Therefore, a low vitrector cut-
rate with gentle manual aspiration should be used, and the
215unfixed sample should be delivered to the cytologist within
one hour.49 If a delay is anticipated, the sample should be
placed in a mild fixative such as Hepes-glutamic acid buffer
mediated Organic solvent Protection Effect (HOPE), which is
preferable to alcohol or formalin fixation.50,51 Many vitreor-
220etinal surgeons also provide dilute vitreous and the vitreous
cassette as additional samples for pathological testing.52
Prior experience in evaluating cytopathological specimens is
valuable, since it is easy to miss the small numbers of malignant
lymphoma cells amongst the larger numbers of reactive lympho-
225cytes and degenerate cells that are invariably present (Figure 2).
Regardless, the sensitivity of vitreous cytology alone in the diag-
nosis of PVRL may be as low as 30%, and many patients require
more than one diagnostic vitrectomy.13,53 Histopathology of
a chorioretinal biopsy has a higher sensitivity, but also
230a considerably higher ocular morbidity than vitrectomy, and is
reserved for exceptional situations.54
In recent years, several supplementary tests on ocular sam-
ples have become extremely beneficial adjuncts to reaching
a diagnosis of PVRL. Interleukin (IL)-10 is a cytokine
235expressed by malignant B-cells, whereas inflammatory cells
produce IL-6. Thus, an elevated IL-10 level, or a relatively
high IL-10:IL-6 ratio in the aqueous or vitreous fluid is quite
suggestive, albeit not diagnostic, of PVRL.55,56 The identifica-
tion of immunoglobulin heavy chain gene rearrangements by
240PCR testing on vitreous samples or chorioretinal biopsy speci-
mens have also proven useful,55,57 and several groups have
demonstrated that a high percentage of PVRL harbor
a mutation in the MYD88 gene, which may be another helpful






diagnostic aid.58–60 Although EBV infection has been asso-
245 ciated with PVRL, role of PCR for EBV on vitreous as an
adjunct to the diagnosis of HIV-related PVRL has not been
established. However, the diagnostic vitrectomy provides an
important opportunity to rule out the presence of intraocular
infection in HIV-positive patients.
250 Evaluation for PCNSL
Due to the strong association between PVRL and PCNSL, all
HIV-positive patients suspected of having PVRL should
undergo brain magnetic resonance imaging (MRI), as well as
CSF analysis for cytology, flow cytometry and EBV PCR.61
255 On MRI, HIV-related PCNSL presents with single or mul-
tiple supratentorial lesions, most commonly with ring
enhancement (Figure 1d).62 If lesions are found, stereotactic
brain biopsy may be used to establish the diagnosis of PCNSL
with concurrent PVRL. However, since this procedure has
260 a high morbidity and mortality in these severely immuno-
compromised HIV patients, vitreous biopsy is often the diag-
nostic procedure of choice.63
Positive CSF cytology and/or flow cytometry identifying
lymphoma cells is diagnostic of PCNSL and could obviate the
265 need for diagnostic vitrectomy.61 A high titer of EBV on CSF
PCR is highly suggestive, but not diagnostic, of PCNSL and may
be used as an indication for diagnostic vitrectomy, even with
normal neuroimaging.4 Notably, HIV-positive patients who
have previously been treated with ganciclovir may have a false-
270negative CSF PCR for EBV in the presence of PCNSL.64
Treatment
The optimum treatment of HIV-related PVRL remains unde-
fined, and the limited evidence on the topic is derived from
retrospective case series. Current approaches involve the com-
275bination of ART and local ocular therapy (intravitreal metho-
trexate, intravitreal rituximab or ocular external beam
radiation), and in selected cases, systemic chemotherapy.65–69
ART forms a critical component of any successful treat-
ment regime in HIV-related PVRL with or without PCNSL.
280Improvements in CD4 count and reduction in HIV viral load
are associated with better disease control and improved over-
all survival.70
HIV-positive patients with PVRL and associated PCNSL
should be treated with systemic chemotherapy, as well as ART
285and local ocular chemotherapy or radiotherapy.39 Following the
British HIV Association Guidelines, patients who are suffi-
ciently fit should receive a high-dose methotrexate-containing
chemotherapy regimen as first-line systemic treatment.61,71,72
Whole-brain radiotherapy has fallen out of favor due to high
290recurrence rates and neuro-cognitive adverse effects, and is
reserved for palliative cases, or those patients in whom the
risks of toxicity from high-dose chemotherapy is considered
unacceptable.73 Although rituximab has effectiveness as
a systemic treatment in HIV-related systemic non-Hodgkin’s
295lymphomas, it does not appear to have similar therapeutic
activity in PCNSL and is associated with high rates of toxicity
in HIV-positive patients with low CD4 counts.74,75
HIV-positive patients with PVRL without associated
PCNSL should be treated with ART and local ocular treat-
300ment, but the addition of systemic chemotherapy remains
uncertain. The local approach minimizes systemic toxicity,
which is a major advantage in HIV-positive individuals, but
a concern is that potential subclinical sites of PCNSL remain
untreated and could lead to earlier CNS involvement with
305reduced survival time.66 In one large early case series of
immunocompetent patients, the International PCNSL
Collaborative Group found that the use of local ocular treat-
ment alone did not compromise disease control or overall
survival.2 In contrast, several small recent studies suggest
310that omission of systemic therapy may lead to earlier CNS
involvement.76,77
It is unclear whether the addition of EBV treatment in
HIV-related PVRL may have value. Small retrospective stu-
dies on HIV-associated PCNSL utilized IL-2 to induce EBV to
315break from latency in the tumor cells and render the virus
susceptible to ganciclovir or foscarnet treatment, and showed
potential benefit.78,79
Prognosis
Although not specifically addressed in the literature, the prog-
320nosis of HIV-related PVRL may be worse than that of PVRL
in immunocompetent patients, with CNS involvement or
other AIDS-related illnesses being the most common sources
of mortality.80 However, prognosis has improved significantly
Figure 2. Vitreous biopsy of a patient with PVRL. (a). Mai-Grunewald Giemsa
(MGG) stain of the cytospin of a vitrectomy sample demonstrating atypical
lymphocytic blasts on a background of lytic cells. The atypical blasts are
pleomorphic with varying-sized nuclei and with narrow cytoplasmic rims. (b).
CD20 stain using DAB chromogen highlighting the atypical cells as neoplastic
B-cells. The background lytic cells are also positive with this stain.






compared to the pre-ART era, when survival was only a few
325 months.4–7,12 Recent studies of HIV-related PCNSL have
shown mean overall survival of up to 60 months.61,72,81
Conclusion
HIV-related PVRL is a rare condition, which is difficult to
diagnose and has a poor prognosis. The ophthalmologist should
330 always consider this diagnosis in HIV-positive patients with
severe immunosuppression who present with undifferentiated
intermediate or posterior uveitis. Large multinational collabora-
tive clinical studies are needed to consolidate optimal diagnostic
investigations and treatment regimens for this serious condition.
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